China’s Pharma Industry Is Now No. 2 in the World
trackcircleChina’s pharmaceutical industry is growing fast. It is now the second largest in the world. An official from the National Medical Products Administration (NMPA) shared this news. About 30% of the world’s innovative drugs in the pipeline are now from China.
Key points
- Strong growth in new drugs: Since 2021, China approved 204 innovative drugs, 387 pediatric drugs, and 147 rare disease drugs. This helps key patient groups get the medicines they need.
- Faster approvals in 2025: In the first seven months of 2025, China approved 50 innovative drugs. This is already more than the 48 approvals in all of last year.
- Focus on serious diseases: Many new drugs target cancer, metabolic disorders, and immune diseases.
- Better safety and quality: China is taking steps to improve drug safety, quality, and supply across the whole value chain.
- Global R&D investment: International pharma companies are investing more in China. Pfizer opened a new R&D center in Beijing. AstraZeneca plans to invest $2.5 billion and set up a global strategic R&D center in the city.
Why this matters
- More choice for patients and hospitals
- Faster access to innovative treatments
- Stronger supply chain and local manufacturing
- Growing R&D talent and technology in China
Simple FAQ
- Who shared the update? NMPA (National Medical Products Administration).
- What rank is China now? Second largest pharma industry in the world.
- What is the pipeline share? Around 30% of global innovative drug pipeline.
- Which areas are growing? Oncology, metabolic, and immune diseases.
- What about global companies? Pfizer and AstraZeneca expanded R&D in Beijing.
Call to action
Want to discuss demand, supply, or partnerships in China, Hong Kong, or Macau? Contact us. We can share data on volume, pricing, and timelines.
